Posted June 7, 2017
A few weeks ago, we told you that the FDA’s Pharmacy Compounding Advisory Committee (PCAC) was meeting once again to decide whether patients will have access to customized medicines. True to form, PCAC voted to reject all the substances that came before them (the meeting minutes aren’t published yet, but you can look at webcasts of the meetings here). PCAC, following the FDA’s guidance, voted to reject artemisinin, nettle, ubiquinol, vanadyl sulfate, and nicotinamide adenine dinucleotide. Read more.